Trials / Active Not Recruiting
Active Not RecruitingNCT01840566
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety of delivering the patients' own immune cells, called T cells, after the high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carmustine | |
| DRUG | Etoposide | |
| DRUG | Cytarabine | |
| DRUG | Melphalan | |
| BIOLOGICAL | Pegfilgrastim | |
| BIOLOGICAL | 19-28z T CELLS | |
| PROCEDURE | Autologous Stem Cell Transplantation |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2013-04-25
- Last updated
- 2025-12-03
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01840566. Inclusion in this directory is not an endorsement.